Literature DB >> 3711499

Percutaneous mitral valvuloplasty in an adult patient with calcific rheumatic mitral stenosis.

R G McKay, J E Lock, J F Keane, R D Safian, J M Aroesty, W Grossman.   

Abstract

A 75 year old man with long-standing rheumatic mitral stenosis who refused surgical intervention was treated with percutaneous balloon valvuloplasty. Prevalvuloplasty evaluation revealed a heavily calcified mitral valve, a mean transvalvular gradient of 18 mm Hg, a Fick cardiac index of 1.7 liters/min per m2, a mitral valve area of 0.6 cm2 and 1 + mitral regurgitation. After transeptal catheterization and balloon dilation of the interatrial septum with an 8 mm angioplasty balloon, a 25 mm valvuloplasty balloon was advanced over a guide wire across the interatrial septum and positioned across the mitral anulus. Subsequent balloon inflation at 3 atm pressure resulted in a reduction of the mean mitral valve gradient to 12 mm Hg, an increase in cardiac index to 2.5 liters/min per m2, an increase in mitral valve area in 1.4 cm2 and an increase in mitral regurgitation from 1 + to 2 +. Valvuloplasty was well tolerated without embolization of clot or valvular debris, and resulted in marked clinical improvement with decreased dyspnea and increased exercise tolerance. Repeat catheterization 2 months after valvuloplasty showed further resolution of pulmonary hypertension and no evidence of valvular restenosis or worsening mitral regurgitation, but detected a small atrial septal defect with a pulmonary to systemic blood flow ratio of 1.8. It is concluded that percutaneous valvuloplasty is possible in the adult patient with calcific rheumatic mitral stenosis, and may result in a significant improvement in valvular function without producing life-threatening complications.

Entities:  

Mesh:

Year:  1986        PMID: 3711499     DOI: 10.1016/s0735-1097(86)80164-4

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

1.  Percutaneous balloon dilatation of calcific aortic valve stenosis: anatomical and haemodynamic evaluation.

Authors:  P Commeau; G Grollier; E Lamy; J P Foucault; C Durand; G Maffei; D Maiza; A Khayat; J C Potier
Journal:  Br Heart J       Date:  1988-02

2.  Percutaneous mitral valvotomy in rheumatic mitral stenosis: a new approach.

Authors:  P Commeau; G Grollier; B Huret; J P Foucault; J C Potier
Journal:  Br Heart J       Date:  1987-08

3.  Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation.

Authors:  G T Wilkins; A E Weyman; V M Abascal; P C Block; I F Palacios
Journal:  Br Heart J       Date:  1988-10

4.  Percutaneous transvenous mitral commissurotomy in elderly mitral stenosis patients. A retrospective study at shahid gangalal national heart centre, bansbari, kathmandu, Nepal.

Authors:  Chandra Mani Adhikari; Rabi Malla; Rajib Rajbhandari; Yadav Kumar Bhatta; Arun Maskey; Suman Thapaliya; Prakash Gurung; Kc Man Bahadur
Journal:  Maedica (Buchar)       Date:  2013-09

Review 5.  Indication and timing of percutaneous mitral balloon valvotomy and the role of atrial fibrillation.

Authors:  J Langerveld; J M P G Ernst; N M van Hemel; W Jaarsma
Journal:  Neth Heart J       Date:  2005-01       Impact factor: 2.380

6.  Percutaneous balloon dilatation in congenital mitral stenosis.

Authors:  L E Alday; E Juaneda
Journal:  Br Heart J       Date:  1987-05

7.  Real Time 3D Echocardiographic Evaluation of Iatrogenic Atrial Septal Defects After Percutaneous Transvenous Mitral Commissurotomy.

Authors:  Sarath Babu Devarakonda; Boochi Babu Mannuva; Rajasekhar Durgaprasad; Vanajakshamma Velam; Vidya Sagar Akula; Latheef Kasala
Journal:  J Cardiovasc Thorac Res       Date:  2015

8.  Percutaneous mitral valvuloplasty using the double balloon technique: immediate results and determinant factors of increasing mitral regurgitation.

Authors:  S J Park; W K Lee; W H Shim; S Y Cho; S J Tahk; S S Kim
Journal:  Korean J Intern Med       Date:  1991-07       Impact factor: 2.884

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.